The Australian Medical Association Limited and state AMA entities comply with the Privacy Act 1988. Please refer to the AMA Privacy Policy to understand our commitment to you and information on how we store and protect your data.

×

Search

×
08 Mar 2019

Researchers at Okayama University, Japan report in the journal Arthritis & Rheumatology that monitoring a particular antigen can be used for predicting relapse of the vascular disease antineutrophil cytoplasmic antibody-associated vasculitis (AAV).

When a bacterial or viral pathogenic molecule is detected, an antibody neutralises it by binding to it. However, autoantibodies are sometimes produced against our own protein and cause autoimmune diseases. 

For the autoantibody known as ANCA (antineutrophil cytoplasmic antibody) cause ANCA-associated vasculitis (AAV), at least two antigens exist: proteinase 3 and myeloperoxidase (abbreviated as PR3 and MPO, respectively).

Assistant Professor Haruki Watanabe and Associate Professor Ken-Ei Sada from Okayama University and colleagues have now investigated whether MPO-ANCA can be used as a biomarker for the relapse of AAV, a blood-vessel inflammation disease. The researchers’ findings suggest that monitoring MPO-ANCA is useful for predicting relapse in patients with AAV.

The scientists looked at data for 271 MPO-ANCA-positive patients who had achieved remission (disappearance of the signs and symptoms) of AAV during six months after therapy was started. Levels of MPO-ANCA were measured at several times in a two-year period.

Assistant Professor Haruki Watanabe and Associate Professor Ken-Ei Sada from Okayama University and colleagues found that for 72 per cent of the patients, MPO-ANCA levels decreased to normal within six months after therapy began.

MPO-ANCA reappeared for 40 per cent of the patients for which there were complete follow-up data; this reappearance was associated with a relapse occurring simultaneously or later. The researchers therefore concluded that reappearance of MPO-ANCA is a promising marker for AAV relapse.

Assistant Professor Haruki Watanabe and Associate Professor Ken-Ei Sada from Okayama University and colleagues found indications that MPO-ANCA reappearance could be particularly useful as a biomarker for relapse of AAV with kidney involvement (renal AAV).  Since only four patients without renal involvement experienced relapse, a larger study would be necessary to establish any link between MPO-ANCA reappearance and relapse of non-renal AAV.

The researchers point out that their study has some limitations: the data were obtained earlier, in the context of other investigations, and different participating institutions used different analytic procedures for qualitatively assessing ANCA content.

Nevertheless, the study was the largest so far, and also the first with case–control analysis (based on comparisons of patients with and without the disease relapse). Professor Watanabe and colleagues conclude that for patients recovered from MPO-AAV: “Routine MPO-ANCA monitoring should be implemented (to predict possible relapse).”

Background

Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) refers to a set of diseases (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), the characteristics of which are destruction and inflammation of small blood vessels. Clinical signs vary, and different organs can be affected, including kidneys, stomach, and lungs. The study has now shown that for patients having had AAV, monitoring the presence of an antigen known as MPO-ANCA should help to predict AAV relapse.

Okayama University is one of the largest comprehensive universities in Japan with roots going back to the Medical Training Place sponsored by the Lord of Okayama and established in 1870. Now with 1,300 faculty and 13,000 students, the University offers courses in specialties ranging from medicine and pharmacy to humanities and physical sciences. Okayama University is located in the heart of Japan approximately three hours west of Tokyo by Shinkansen.


Published: 08 Mar 2019